← Back to Search

MARVIN CHAMP: a Chatbot for Pediatric Infectious Conditions for Human Immunodeficiency Virus Infection

N/A

Recruiting

Led By Bertrand Lebouché, MD

Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up once every 3 months within 12 months

Awards & highlights

Study Summary

This trial aims to expand the use of the MARVIN chatbot to other health areas like breast cancer and different populations like pharmacists. They will use a flexible trial design to test different interventions and may

Who is the study for?

This trial is for adults over 18 who speak English or French, can consent to participate, and have access to a device with internet. They must be willing to use Facebook Messenger-based chatbots and accept Facebook's privacy policies.Check my eligibility

What is being tested?

The study tests different MARVIN chatbots (MARVIN, MARVIN-Pharma, MARVINA, MARVIN-CHAMP) designed for various health conditions like breast cancer and HIV. It uses an adaptive platform trial design allowing changes based on early results.See study design

What are the potential side effects?

Since this trial involves informational chatbots rather than medical treatments, traditional side effects are not applicable. However, participants may experience issues related to data privacy or emotional discomfort from discussing health conditions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ once every 3 months within 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~once every 3 months within 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and once every 3 months within 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acceptability E-Scale (AES)

Change in Acceptability E-Scale (AES) over 12 months

Change in Compatibility Subscale over 12 months

+2 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: MARVINA: a Chatbot for Breast Cancer PatientsExperimental Treatment1 Intervention

Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

Group II: MARVIN: a Chatbot for HIV patientsExperimental Treatment1 Intervention

Co-construction of the chatbot, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

Group III: MARVIN: a Chatbot for Community PharmacistsExperimental Treatment1 Intervention

Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

Group IV: MARVIN CHAMP: a Chatbot for Pediatric Infectious ConditionsExperimental Treatment1 Intervention

Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)OTHER

366 Previous Clinical Trials

129,237 Total Patients Enrolled

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor

447 Previous Clinical Trials

159,352 Total Patients Enrolled

Bertrand Lebouché, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

3 Previous Clinical Trials

155 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment of participants ongoing for this study?

"Indeed, details on clinicaltrials.gov show that this trial is actively searching for participants. The trial was initially listed on March 1st, 2024 and last updated on March 4th, 2024. They aim to recruit a total of 400 patients at two distinct sites."

Answered by AI

What is the upper limit of individuals partaking in this research endeavor?

"Indeed, the information available on clinicaltrials.gov indicates that this particular research study is actively seeking eligible participants. The trial was initially posted on March 1st, 2024 and most recently updated on March 4th, 2024. In total, the study aims to enroll 400 patients across two distinct sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The MARVIN Chatbots to Provide Information for Different Health Conditions

Dr. Bertrand Lebouche 2024. "The MARVIN Chatbots to Provide Information for Different Health Conditions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05789901.